Johnson & Johnson Barely Pulls Through on Strong Pharma Sales

Health and Healthcare

Published: January 20, 2015 8:30 am

Last Updated: January 20, 2015 8:33 am

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter results Tuesday before the market open as $1.27 in earnings per share (EPS) on $18.6 billion in revenue. That was against Thomson Reuters consensus estimates of $1.26 in EPS and revenue of $18.55 billion. In the fourth quarter of the previous year, the company posted EPS of $1.24 and $18.36 billion in revenue.

The company gave guidance for 2015 EPS in the range of $6.12 to $6.27. The consensus estimate for 2015 earnings per share is $6.13.

Worldwide sales for the 2014 full-year were up 4.2% to $74.3 billion. Contributing to this were worldwide consumer sales of $14.5 billion, down 1.4%, and worldwide pharmaceutical sales of $32.3 billion, up 14.9%. Worldwide Medical Devices sales were $27.5 billion, which was a decrease from the previous year of 3.4%.

ALSO READ: Merck Is Top Dow Stock So Far in 2015

The strong drug sales results were driven by new products, along with the solid core products. New products that played a role in this growth were:

Olysio/Sovriad (simeprevir), combination treatment of chronic hepatitis C in adult patients
Xarelto (rivaroxaban), oral anticoagulant
Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer
Invokana (canagliflozin), for the treatment of adults with type 2 diabetes
Imbruvica (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers

Alex Gorsky, chairman and CEO, said:

2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our Pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our Medical Devices business and are continuing our market leadership with iconic brands in our Consumer business.

24/7 Wall St. includes recent analyst calls and rating for your consideration:

Barclays maintained an Equal Weight rating and raised its price target to $103 from $102 on January 16.
Jefferies maintained a Hold rating and lowered its price target to $113 from $114 on January 15.
Goldman Sachs downgraded Johnson & Johnson to a Sell rating from Neutral and set a price target of $97 on January 15.

ALSO READ: The Bullish and Bearish Case for Pfizer in 2015

Shares of Johnson & Johnson closed Friday up 1.5% at $104.04. Following the release of the earnings report, the initial response in the premarket was negative and shares were down 1% at $103.10.

The company’s stock has a consensus analyst price target of $109.07 and a 52-week trading range of $86.09 to $109.49. The market cap is about $291 billion.

The Average American Is Losing Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.

Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.

But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.